November 8, 2022 / Clinical Trials

Astellas Announces Decision to Discontinue Screening & Enrollment Activities for ASP0367 (MA-0211)

PPMD is disappointed to learn that Astellas has announced its decision to discontinue further screening and enrollment activities for ASP0367 (MA-0211) in participants with Duchenne.

This decision was not based on safety concerns, but due to the design of a clinical trial that proved challenging for families to enroll in.

Astellas assures the Duchenne community that they are working to provide an open forum to ask questions and address concerns, while continuing to work with families to improve its overall development strategy and alleviate enrollment hurdles for the future.

Click here to read the full community letter.

Join Our Mailing List